Molnupiravir Armageddon

Molnupiravir Extends COVID-19 Viral Phase, Evidenced by the High Frequency of Rare and Dangerous Mutations in SARS-COV-2, preprint, 2021-12-20

Unexpected Mildness of Host-Induced Mutations in SARS-COV-2, preprint, 2021-12-08

Treating a Pandemic Respiratory Disease with a Mutagen is a Doomsday Scenario, preprint, 2021-12-02

AMDAC used the decision-making process in authorization of Remdesivir (Remdeathivir) as the precedent for decision-making on Molnupiravir not knowing that Remdesivir is harmful, and its authorization was corrupt.

12/6/2021 

BTW, the heterogeneity of the claimed results by country shows that Merck’s claims of Molnupiravir efficacy are incorrect

In Guatemala, 5 out of 55 Molnupiravir arm subjects were hospitalized or died, compared with 0 out of 58 in the placebo arm.

Early versions

molnupiravir-armageddon-0.9.5.pdf

molnupiravir-armageddon-0.9.pdf

Leave a Reply

Your email address will not be published. Required fields are marked *